Pharmaceutical Technology E-Alert:
Having trouble viewing this e-mail? Click here.
BLOG
EVENT CALENDAR
COLUMNS
WHITE PAPERS
THE MAGAZINE
  Pharmaceutical Technology Europe E-Alert
 
20 July 2012

IN THIS ISSUE
• GSK and HGS
• Global Medicine Use
• AstraZeneca Workers
• Par Pharmaceuticals

GSK to Acquire Human Genome Sciences for $3.6 Billion
GlaxoSmithKline has announced that it will acquire Human Genome Sciences (HGS) for $14.25 per share in cash, or approximately $3.6 billion on an equity basis. More...
 
IMS Forecasts for Global Medicine Use
A report from the IMS Institute for Healthcare Informatics, The Global Use of Medicines: Outlook through 2016, found that annual global spending on medicines will rise from $956 billion in 2011 to nearly $1.2 trillion in 2016. More...
 
EC Offers Aid to Former AstraZeneca Workers in Sweden
The European Commission is looking to provide Sweden with EUR4.3 million to help 700 workers affected by AstraZeneca job cuts to find new work. More...
 
Par Pharmaceuticals to be Acquired by TPG for $1.9 Billion
Par Pharmaceuticals, a maker of generic drugs, has entered into an agreement to be acquired by the private investment firm, TPG. More...
 
All atweet!
Keep up to date with the latest news, gossip and rumours hitting the web about the pharmaceutical industry by following us on Twitter. More...
Key Topics:

Latest blog posts
GSK's Olympic Role
The Potential of Big Data
Limited Enforcement
More blog posts

Latest articles
Analytical Tools for a Quality-by-Design Approach to Lyophilization
Defining Design Space in Hot-Melt Extrusion
A Practical Guide to Pan Coating and Scale-Up
More articles

Upcoming events
REACH and CLP USA (1–2 August | US)
CPhI South America (21–23 August | Brazil)
Pharmaceutical Regulatory Summit (21–24 August | Singapore)
More events

Products/Service Profiles
Pharmaceutical Press

Handbook of Pharmaceutical Excipients, NEW 7th edition. Special offer price - available now.
A new edition of the Handbook has always seen important developments, and this edition is no exception. Not only has the entire volume been reviewed and updated, significant new content has been added.
Read more
Survey
Are you in favor of the US Supreme Court overturning the Affordable Care Act and its associated biosimilars pathway?
 
Yes 74%
 
 
No 21%
     
 
I am in favour of overturning the Act but keeping the biosimilars pathway in tact 5%

This week we would like to know...

Has your manufacturing site implemented an energy efficiency plan to reduce carbon footprint?

Click here to vote

Contact Us
Click here to contact editorial.

Click here to contact sales.